A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus

Samantha Brandler Grolleau, Claude Ruffie, Chantal Combredet, Jean-Baptiste Brault, Valerie Najburg, Marie Christine Prevost, Andre Habel, Erich Tauber, Philippe Despres, Frederic Tangy

Research output: Contribution to journalArticleResearchpeer-review

109 Citations (Scopus)


Chikungunya virus (CHIKV), a mosquito-transmitted alphavirus, recently reemerged in the Indian Ocean, India and Southeast Asia, causing millions of cases of severe polyarthralgia. No specific treatment to prevent disease or vaccine to limit epidemics is currently available. Here we describe a recombinant live-attenuated measles vaccine (MV) expressing CHIKV virus-like particles comprising capsid and envelope structural proteins from the recent CHIKV strain La Reunion. Immunization of mice susceptible to measles virus induced high titers of CHIKV antibodies that neutralized several primary isolates. Specific cellular immune responses were also elicited. A single immunization with this vaccine candidate protected all mice from a lethal CHIKV challenge, and passive transfer of immune sera conferred protection to naive mice. Measles vaccine is one of the safest and most effective human vaccines. A recombinant MV-CHIKV virus could make a safe and effective vaccine against chikungunya that deserves to be further tested in human trials
Original languageEnglish
Pages (from-to)3718 - 3725
Number of pages8
Issue number36
Publication statusPublished - 2013
Externally publishedYes

Cite this